ORKA Company Profile and Key Details

ORKA has shown sold momentum, gaining 8.28% over the past week and 20.92% over the past quarter, though year-to-date performance is up 9.63%. Short-term trend indicators are bearishly aligned (SMA20 2.88%, SMA50 7.38%, SMA200 57.69%). The stock’s 14-day RSI is 56.41 (neutral), while the ATR of 1.96 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.05% below its high and over 525.71% above its low. Average 10-day trading volume of 1.05 million shares is below the 3-month average of 1.69 million, indicating normal recent market interest.

Oruka Therapeutics, Inc. has 60.31 million shares outstanding. The public float is 51.09 million shares, elevated short interest at 22.32% of float. This equals 8.83 million shares. The short ratio is 4.99 days. Institutional investors hold 90.82% of the float. Insiders own 1.23%. Venrock Healthcare Capital Partners III, L.P. holds 4.15 million shares, Fairmount Funds Management LLC has 1.13 million shares and Klein Lawrence Otto has 925.58 thousand shares. Over the past six months, insider transactions show net selling. They sold 3.62 million shares across 24 transactions.

Oruka Therapeutics, Inc. last paid a dividend of 19.36 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.99. This means the shares are trading above this model’s fair value.

Oruka Therapeutics, Inc. generated EPS of -$2.42 over the past year. Five-year average earnings growth is 36.88%. Wall Street analysts project EPS growth of 9.89% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 9 Strong Buy ratings, 27 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $160.00 to $40.00. The high target offers 77.38% upside. The low target suggests -55.65% downside. The mean target is $84.78. This offers -6.01% upside. Oruka Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 13, 2026, missed forecasts by -7.69%. The prior quarter beat by -26.23%. Over the last six quarters, Apple has recorded several small beats. These include -27.94% in March 06, 2025.

Oruka Therapeutics, Inc. (NASDAQ:ORKA) closed at $90.20 USD, losing -$1.96 (-2.13%) from the previous close of $92.16. The stock is currently mid-range between its 52-week high and low $12.84 and $97.78. With a market capitalization of about $3.38 billion, Oruka Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-0.40). Key stats such as the average daily volume over the past year has been around 1.67 million shares, volume is running light vs its 52-week average. Headquartered in Menlo Park, CA, Oruka Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Lawrence Otto Klein, the company employs approximately 68 people and listed since August 08, 1997. Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Our AI price prediction model suggests that Oruka Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.57%, with price expected at $95.22 by August 07, 2026, within a range of $90.21 to $99.94 3-Month Outlook: Projected rise of 87.95%, reaching $169.53 by October 22, 2026, with a range of $168.81 to $170.43. 1-Year Outlook: Projected gain of 13.43%, with price at $102.31 by July 23, 2027, within a range of $97.54 to $108.47.

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares are flat 9.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Oruka Therapeutics, Inc. trading at a premium to the broader market with a P/E of -38.41. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $75.46, suggesting -16.34% downside. Our AI forecast model points to short-term strength (5.57% over two weeks), a medium-term rise (87.95% over three months), and a longer-term gain (13.43% over one year), with expected trading ranges indicating moderate volatility.

Oruka Therapeutics, Inc. trades at a P/E ratio of -38.41, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 10.4 reflecting a rich premium to book value. The P/FCF stands at -37.7, also below market averages. Compared to sector medians, Oruka Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.